• Received 5 purchase orders, 4 for HiRise™ device
• FDA 510(k) clearance for BMD module delayed to H2 CY26
• On track for NMPA clearance of HiRise™ in China in H2 CY26

CurveBeam AI Limited (ASX: CVB) announced its Appendix 4C and quarterly activity report for the period ended 31 March 2026 (Q3 FY26). The company received purchase orders (POs) for five devices in Q3 FY26, four of which were for the HiRise™ device. The company has received feedback on its FDA 510(k) application for the BMD module for multi-detector computed tomography (MDCT) scans and is compiling the requested clinical review and supplemental analysis, with clearance now targeted for H2 CY26. The company also received feedback on its HiRise™ application from the National Medical Products Administration (NMPA) in China and remains on track for clearance in the second half of the calendar year. This milestone would enable HiRise™ sales in China and trigger another milestone payment, with further payments expected as sales orders follow. The company made progress in advancing its total hip arthroplasty (THA) protocol for one of the other four leading robotic surgery systems and is collaborating with several other TKA, THA and general surgical solutions providers. Cashflows used in operations for Q3 FY26 was A$4.209m, with a cash balance of A$4.311m at the end of the quarter.